# EDGAR Filing Document

**Accession Number:** 0001482981
**File Stem:** 0001482981-23-000011
**Filing Date:** 2023-3
**Character Count:** 40720
**Document Hash:** 3822548e40203d5934de9e4ba2f1935a
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001482981-23-000011.hdr.sgml**: 20230308

**ACCESSION NUMBER**: 0001482981-23-000011

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 14

**CONFORMED PERIOD OF REPORT**: 20230308

**ITEM INFORMATION**: Results of Operations and Financial Condition

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20230308

**DATE AS OF CHANGE**: 20230308

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Vita Coco Company, Inc.
- **CENTRAL INDEX KEY:** 0001482981
- **STANDARD INDUSTRIAL CLASSIFICATION:** BEVERAGES [2080]
- **IRS NUMBER:** 113713156
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-40950
- **FILM NUMBER:** 23714861

**BUSINESS ADDRESS:**
- **STREET 1:** 39 WEST 14TH STREET, SUITE 404
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10011
- **BUSINESS PHONE:** 212-206-0763

**MAIL ADDRESS:**
- **STREET 1:** 39 WEST 14TH STREET, SUITE 404
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10011

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** All Market Inc.
- **DATE OF NAME CHANGE:** 20210824

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** All Market, Inc.
- **DATE OF NAME CHANGE:** 20210824

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Vita Coco Company, Inc.
- **DATE OF NAME CHANGE:** 20210823

?xml version="1.0" ? coco-20230308

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

_____________________________

**FORM 8-K**

_____________________________

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d)**

**of the Securities Exchange Act of 1934**

**Date of report (Date of earliest event reported): March 8, 2023**

_____________________________

**The Vita Coco Company, Inc.**

**(Exact name of registrant as specified in its charter)**

_____________________________

---

| | | |
|:---|:---|:---|
| **Delaware** | **001-40950** | **11-3713156** |
| **(State or other jurisdiction of**<br>**incorporation)** | **(Commission**<br>**File Number)** | **(I.R.S. Employer**<br>**Identification No.)** |

---

**250 Park Avenue South**

**Seventh Floor**

**New York, New York 10003**

**(Address of principal executive offices) (Zip Code)**

**(Registrant's telephone number, include area code) (212) 206-0763**

**N/A**

**(Former Name or Former Address, if Changed Since Last Report)**

_____________________________

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading**<br>**Symbols** | **Name of each exchange**<br>**on which registered** |
| **Common Stock, $0.01 par value per share** | **COCO** | **The Nasdaq Stock Market LLC** |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ⌧

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

------

**Item 2.02&nbsp;&nbsp;&nbsp;&nbsp;Results of Operations and Financial Condition.**

On March 8, 2023, The Vita Coco Company, Inc. (the "Company") issued a press release announcing financial results for the three months and year ended December 31, 2022 and other matters described in the press release. A copy of the Company's press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference.

The information disclosed under this Item 2.02, including Exhibit 99.1 hereto, is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall it be incorporated by reference into any registration statement or other document pursuant to the Securities Act of 1933, as amended, except as expressly set forth in such filing.

**Item 9.01&nbsp;&nbsp;&nbsp;&nbsp;Financial Statements and Exhibits.**

(d)Exhibits.

---

| | |
|:---|:---|
| **Exhibit No.** | **Description** |
| 99.1 | <u>[Press release, dated March](coco-20221231xexx991pressr.htm)[8](coco-20221231xexx991pressr.htm)[, 202](coco-20221231xexx991pressr.htm)[3](coco-20221231xexx991pressr.htm)[.](coco-20221231xexx991pressr.htm)</u> |
| 104 | Cover Page Interactive Data File (embedded with Inline XBRL document) |

---

------

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | THE VITA COCO COMPANY, INC. | THE VITA COCO COMPANY, INC. |
| Date: March 8, 2023 | By: | /s/ Rowena Ricalde |
|  |  | Name: Rowena Ricalde |
|  |  | Title: Interim CFO |

---

## Exhibit 99.1

**Exhibit 99.1**

![image_0.jpg](image_0.jpg)

**The Vita Coco Company Reports Fourth Quarter and Full Year 2022 Financial Results**

*Full Year Net Sales Increased 13% to $428 million Driven by Vita Coco Coconut Water Growth of 18%*

*Full Year Net Income of $8 million and Full Year Non-GAAP Adjusted EBITDA*<sup>1</sup> *of $20 million Consistent with Guidance*

*For Fiscal Year 2023, Expect Significant Cost of Goods Improvements and Adjusted EBITDA*<sup>2</sup> *between $52-58 million*

**NEW YORK, NY – March 8, 2023 –** The Vita Coco Company, Inc. (NASDAQ:COCO) ("Vita Coco" or "the Company"), a leading high-growth platform of better-for-you beverage brands, today announced financial results for the fourth quarter and full year ended December 31, 2022.

**Fourth Quarter 2022 Highlights Compared to Prior Year**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Net sales grew 6% to $92 million, slightly exceeding expectations, driven by *Vita Coco* Coconut Water growth of 4%

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Gross profit was flat to prior year at $22 million, or 24% of net sales versus 25% of net sales

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Net loss attributable to shareholders was $(3) million, or $(0.05) per diluted share, compared to a net loss attributable to shareholders of $(3) million, or $(0.06) per diluted share

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Non-GAAP Adjusted EBITDA<sup>1</sup> was $4 million compared to $1 million

**Full Year 2022 Highlights Compared to Prior Year**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Net sales grew 13% to $428 million driven by *Vita Coco* Coconut Water growth of 18%

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Gross profit decreased to $103 million, or 24% of net sales, from $113 million, or 30% of net sales, with the decrease driven by higher year-over-year transportation costs

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Net income attributable to shareholders was $8 million, or $0.14 per diluted share, compared to $19 million, or $0.35 per diluted share

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Non-GAAP Adjusted EBITDA<sup>1</sup> was $20 million compared to $37 million due primarily to higher transportation and ongoing incremental public company costs

Michael Kirban, the Company's Co-founder and Executive Chairman, stated, "I am very proud of our team's performance during a challenging supply chain environment in 2022, and I'm very excited that in early 2023 we are starting to see those challenges ease. I'm especially happy with our strong *Vita Coco* Coconut Water net revenue growth of 18% for the year, building on a very strong brand performance in 2021. On a three-year basis, our fourth quarter *Vita Coco* Coconut Water net sales grew 115%, and our full year net sales grew 72% over the same period in 2019, demonstrating the underlying health of our brand. In 2023, we expect continued growth on our *Vita Coco* Coconut Water net sales, improvement of our gross margin as we improve our supply chain costs throughout the year, and substantial progress in improving our Adjusted EBITDA. We are committed to our long-term ambition to create and maintain category leading brands in the broader better-for you, functional beverage segment and we see 2023 as a year where we invest behind our opportunities."

Martin Roper, the Company's Chief Executive Officer, said, "We are pleased with our 2022 results. Gross margins for the quarter benefited from front line pricing actions during the year, but were impacted by temporary supply chain costs related to our inventory build. We have seen these inventory related expenses recede during the first months of 2023. By the end of the year we expect inventories to return to more normal levels. We are happy that our *Vita Coco* brand remains very healthy, and our key 2023 commercial initiatives that support our 2023 guidance are progressing positively. As a result of favorable trends on demand and costs, we intend to increase our investment in marketing and sales execution in to order to maintain our momentum."

------

**Fourth Quarter 2022 Consolidated Results**

Net sales increased $5 million, or 6%, to $92 million for the fourth quarter ended December 31, 2022, compared to $87 million for the fourth quarter ended December 31, 2021. The increase in net sales was driven by increased case equivalent ("CE") volumes coupled with some benefits from net pricing actions offset by product mix and promotional timing.

Gross profit was $22 million for the fourth quarter of 2022, which was flat compared to the fourth quarter of 2021. Gross margin of 24.4% in the fourth quarter decreased slightly from 24.9% in the same period last year, with both periods experiencing temporary increased domestic transportation costs in addition to the significant increases in ocean freight rates.

Selling, general and administrative expenses ("SG&A") in the fourth quarter of 2022 were $27 million, compared to $27 million in the same prior year period. The fourth quarter of 2022 included a non-cash intangible asset impairment charge of $7 million related to Runa trademarks and distributor relationships and a benefit compared to fourth quarter of 2021 from lower bonuses and marketing.

Net loss attributable to shareholders was $(3) million, or $(0.05) per diluted share, for the fourth quarter of 2022, compared to a net loss of $(3) million, or $(0.06) per diluted share, in the fourth quarter of 2021. Net income was positively impacted by a foreign currency gain and a non-cash mark-to-market gain in fair value on foreign currency hedges.

Adjusted EBITDA<sup>1</sup> for the fourth quarter of 2022 was $4 million, compared to $1 million in the fourth quarter of 2021. The increase in Adjusted EBITDA<sup>1</sup> was primarily driven by reduced SG&A costs.

**Full Year 2022 Consolidated Results**

Net sales increased $48 million, or 13%, to $428 million for the year ended December 31, 2022, compared to $380 million for the year ended December 31, 2021. The increase in net sales was driven by higher *Vita Coco* Coconut Water CE volumes across both the Americas and International segments.

Strong top line growth driven by the continued underlying strength of our *Vita Coco* brand was offset by increased transportation costs primarily due to global shipping cost pressures and increased domestic transportation costs, including congested ports and warehouses. As a result, gross profit decreased by $10 million, or 9%, to $103 million for the year ended December 31, 2022, from $113 million for the year ended December 31, 2021. Gross margin was 24.2% for the year ended December 31, 2022, as compared to 29.8% for the year ended December 31, 2021.

SG&A expenses increased by $12 million, or 13%, to $100 million for the year ended December 31, 2022, from $89 million for the year ended December 31, 2021. The increase was primarily driven by a net increase in people costs, a full year of ongoing public company costs and a non-cash intangible asset impairment charge of $7 million related to the Runa trademarks and distributor relationships, partially offset by non-recurring IPO readiness expenses in 2021.

Net income attributable to shareholders was $8 million, or $0.14 per diluted share for the year ended 2022, compared to $19 million, or $0.35 per diluted share in the prior year. The decrease versus prior year was primarily driven by the decrease in gross profit from increased transportation costs, an increase in SG&A expenses, partially offset by the favorable impact of the non-cash mark-to-market gain in fair value on foreign currency hedges.

Adjusted EBITDA<sup>1</sup> for the year ended 2022 was $20 million, compared to $37 million in 2021. The decrease in Adjusted EBITDA<sup>1</sup> was primarily driven by higher transportation costs and the incremental impact of a full year of public company costs.

**Balance Sheet**

As of December 31, 2022, the Company had cash and cash equivalents of $20 million, compared to $29 million as of December 31, 2021. There was no debt as of December 31, 2022 and 2021. The decrease in net cash was primarily driven by higher working capital needs. Inventories as of December 31, 2022 totaled $84 million. On December 31, 2022, there were 56,019,050 shares of common stock outstanding.

**Fiscal Year 2023 Full Year Outlook** 

The Company is providing the following guidance:

------

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Expect net sales growth of approximately of 9-11% compared to fiscal year 2022, with Vita Coco Coconut Water expected to grow mid-teens and Private Label net sales approximately flat.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Full year gross margin expected to be between 32% and 34%, with first quarter expected to approach 30%, showing significant improvement over 2022, and sequential improvement expected in the next two quarters, due primarily to improvement in transportation costs, with contributions from price and mix.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Higher full year SG&A expenses to support long term growth initiatives, build commercial capabilities, cover increased employee costs, and improve efficiencies with GAAP reported SG&A expenses growing ahead of net sales.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Forecasting Adjusted EBITDA in the range of $52 million to $58 million<sup>2.</sup>

Uncertainty and instability of the current operating environment, global economies, and geopolitical landscape could affect this outlook and our future results.

**Footnotes:**

(1)Adjusted EBITDA represents earnings before income, taxes, depreciation, and amortization as adjusted for certain items as set forth in the reconciliation table of U.S. GAAP to non-GAAP information and is a measure calculated and presented on the basis of methodologies other than in accordance with GAAP. Please refer to the Use of Non-GAAP Financial Information herein for further discussion and reconciliation of this measure to GAAP measures.

(2)GAAP Net Income 2023 outlook is not provided due to the inherent difficulty in quantifying certain amounts due to a variety of factors including the unpredictability in the movement in foreign currency rates, as well as future charges or reversals outside of the normal course of business.

**Conference Call and Webcast Details**

The Vita Coco Company will host a conference call and webcast at 8:30 a.m. ET today to discuss these results. To participate in the live earnings call and question and answer session, please register at https://register.vevent.com/register/BIa79870562b5d477d9bec9713d5ee646c and dial-in information will be provided directly to you. A slide presentation to support the webcast, and the live audio webcast will be accessible in the "Events" section of the Company's Investor Relations website at https://investors.thevitacococompany.com. An archived replay of the webcast will be available shortly after the live event has concluded.

**About The Vita Coco Company**

The Vita Coco Company was co-founded in 2004 by Chairman Michael Kirban and Ira Liran. Pioneers in the functional beverage category, The Vita Coco Company's brands include the leading coconut water, Vita Coco; clean energy drink Runa; sustainable enhanced water, Ever & Ever; and protein-infused water, PWR LIFT. With its ability to harness the power of people and plants, while balancing purpose and profit, The Vita Coco Company has created a modern beverage platform built for current and future generations.

The company is incorporated as a Public Benefit Corporation in Delaware and is a Certified B Corporation™.

**Contacts**

Investor:

ICR, Inc.

investors@thevitacococompany.com

**Non-GAAP Financial Measures**

In addition to disclosing results determined in accordance with U.S. GAAP, the Company also discloses certain non-GAAP results of operations, including, but not limited to, Adjusted EBITDA, that include certain adjustments or exclude certain charges and gains that are described in the reconciliation table of U.S. GAAP to non-GAAP information provided at the end of this release. These non-GAAP measures are a key metric used by management and our board of directors to assess our financial performance across reporting periods on a consistent basis by excluding items that we do not believe are indicative of our core operating performance and because we believe it is useful for investors to see the measures that management uses to evaluate the Company. In addition, we believe the presentation of these measures is useful to investors

------

for period-to-period comparisons of results as the items described below in the reconciliation tables do not reflect ongoing operating performance.

These measures are not in accordance with, or an alternative to, U.S. GAAP, and may be different from non-GAAP measures used by other companies. In addition, other companies, including companies in our industry, may calculate such measures differently, which reduces its usefulness as a comparative measure. Investors should not rely on any single financial measure when evaluating our business. This information should be considered as supplemental in nature and is not meant as a substitute for our operating results in accordance with U.S. GAAP. We recommend investors review the U.S. GAAP financial measures included in this earnings release. When viewed in conjunction with our U.S. GAAP results and the accompanying reconciliations, we believe these non-GAAP measures provide greater transparency and a more complete understanding of factors affecting our business than U.S. GAAP measures alone.

**Forward-Looking Statements**

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including but not limited to, statements regarding our future financial and operating performance, including our GAAP and non-GAAP guidance, our strategy, projected costs, prospects, expectations, plans, objectives of management, supply chain predictions and expected net sales and category share growth.

The forward-looking statements in this release are only predictions. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our business, financial condition and results of operations. Forward-looking statements involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Forward-looking statements involve a number of risks, uncertainties or other factors beyond the Company's control. These factors include, but are not limited to, those discussed under the caption "Risk Factors" in our Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q and our other filings with the U.S. Securities and Exchange Commission ("SEC") as such factors may be updated from time to time and which are accessible on the SEC's website at www.sec.gov and the Investor Relations page of our website at www.vitacoco.com. Any forward-looking statements contained in this press release speak only as of the date hereof and accordingly undue reliance should not be placed on such statements. We disclaim any obligation or undertaking to update or revise any forward-looking statements contained in this press release, whether as a result of new information, future events or otherwise, other than to the extent required by applicable law.

**Website Disclosure** 

We intend to use our websites, vitacoco.com and investors.thevitacococompany.com, as a means for disclosing material non-public information and for complying with the SEC's Regulation FD and other disclosure obligations.

------

**THE VITA COCO COMPANY, INC.**

**CONSOLIDATED BALANCE SHEETS**

**(Amounts in thousands, except share data)**

---

| | | |
|:---|:---|:---|
| | **December 31,<br>2022** | **December 31,<br>2021** |
| **Assets** | | |
| Current assets: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Cash and cash equivalents | $19629 | $28690 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accounts receivable, net of allowance of $2,898 at December 31, 2022, and $1,301 at December 31, 2021 | 43350 | 47195 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Inventory | 84115 | 75360 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Supplier advances | 1534 | 1170 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Derivative assets | 3606 | 126 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Asset held for sale | 503 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Prepaid expenses and other current assets | 22181 | 20718 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total current assets | 174918 | 173259 |
| Property and equipment, net | 2076 | 2473 |
| Goodwill | 7791 | 7791 |
| Intangible assets, net |  | 7934 |
| Supplier advances | 4360 | 2808 |
| Deferred tax assets, net | 4256 | 1265 |
| Right-of-Use Asset | 2679 |  |
| Other assets | 1677 | 1954 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total assets | $**197757** | $**197484** |
| **Liabilities and Stockholders' Equity** |  |  |
| Current liabilities: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accounts payable | $15910 | $28338 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accrued expenses | 38342 | 42399 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Notes payable, current | 23 | 28 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Derivative liabilities | 71 | 3197 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total current liabilities | **54346** | **73962** |
| Credit facility |  |  |
| Notes payable | 25 | 48 |
| Other long-term liabilities | 2293 | 301 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total liabilities | $**56664** | $**74311** |
| Stockholders' equity: |  |  |
| Common stock, $0.01 par value; 500,000,000 shares authorized; and 62,225,250 shares and 61,764,582 shares issued at December 31, 2022 and 2021, respectively; 56,019,050 and 55,558,382 shares outstanding at December 31, 2022 and 2021, respectively. | 622 | 618 |
| Additional paid-in capital | 145210 | 134730 |
| Retained earnings | 55183 | 47369 |
| Accumulated other comprehensive loss | (994) | (616) |
| Treasury stock, 6,206,200 shares at cost as of December 31, 2022, and December 31, 2021 | (58928) | (58928) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total stockholders' equity attributable to The Vita Coco Company, Inc. | **141093** | **123173** |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total liabilities and stockholders' equity | $**197757** | $**197484** |

---

------

**THE VITA COCO COMPANY, INC.**

**CONSOLIDATED STATEMENTS OF OPERATIONS**

**(Amounts in thousands, except for share and per share data)**

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three Months Ended December 31,** | **Three Months Ended December 31,** | **Twelve Months Ended December 31,** | **Twelve Months Ended December 31,** |
| | **2022** | **2021** | **2022** | **2021** |
| Net sales | $91991 | $86584 | $427787 | $379513 |
| Cost of goods sold | 69558 | 64997 | 324426 | 266365 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Gross profit | 22433 | 21587 | 103361 | 113148 |
| Operating expenses |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Selling, general and administrative | 27288 | 26662 | 100306 | 88559 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total operating expenses | 27288 | 26662 | 100306 | 88559 |
| Income from operations | (4855) | (5075) | 3055 | 24589 |
| Other income (expense) |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Unrealized gain/(loss) on derivative instruments | 190 | 843 | 6606 | 2093 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Foreign currency gain/(loss) | 1895 | (75) | 1387 | (2088) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Loss on extinguishment of debt |  | (132) |  | (132) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Interest income | 21 | 23 | 51 | 127 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Interest expense | (45) | (41) | (258) | (360) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total other income (expense) | 2061 | 618 | 7786 | (360) |
| Income before income taxes | (2794) | (4457) | 10841 | 24229 |
| Income tax expense | (16) | 1040 | (3027) | (5237) |
| Net income | $(2810) | $(3417) | $7814 | $18992 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net income/(loss) attributable to noncontrolling interest |  |  |  | (23) |
| Net income attributable to The Vita Coco Company, Inc. | $(2810) | $(3417) | $7814 | $19015 |
| Net income attributable to The Vita Coco Company, Inc. per common share |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Basic | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;$(0.05) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;$(0.06) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;$0.14 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;$0.35 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Diluted | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;$(0.05) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;$(0.06) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;$0.14 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;$0.35 |
| Weighted-average number of common shares outstanding |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Basic | 55951237 | 54963697 | 55732619 | 53689910 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Diluted | 56405035 | 55521024 | 56123661 | 54186121 |

---

------

**THE VITA COCO COMPANY, INC.**

**CONSOLIDATED STATEMENTS OF CASH FLOWS**

**(Amounts in thousands)**

---

| | | |
|:---|:---|:---|
| | **Twelve Months ended December 31,** | **Twelve Months ended December 31,** |
| | **2022** | **2021** |
| **Cash flows from operating activities:** |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net income | $7814 | $18992 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Adjustments to reconcile net income to net cash provided by operating activities: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Depreciation and amortization | 1901 | 2069 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(Gain)/loss on disposal of equipment | 1 | 112 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Bad debt expense | 2641 | 76 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Unrealized (gain)/loss on derivative instruments | (6606) | (2093) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Stock-based compensation | 7384 | 3380 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Impairment loss on assets held for sale | 619 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Impairment of intangible assets | 6714 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Deferred tax expense/(benefit) | (3081) | (1644) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Noncash lease expense | 1058 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Loss on extinguishment of debt |  | 132 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Changes in operating assets and liabilities: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accounts receivable | 321 | (16917) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Inventory | (9333) | (43501) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Prepaid expenses, net supplier advances, and other assets | (3592) | 2725 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accounts payable, accrued expenses, and other long-term liabilities | (16776) | 20503 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net cash provided by (used in) operating activities | (10935) | (16166) |
| **Cash flows from investing activities:** |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Cash paid for property and equipment | (982) | (557) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Proceeds from sale of property and equipment |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net cash used in investing activities | (982) | (557) |
| **Cash flows from financing activities:** |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Proceeds from issuance of common stock upon initial public offering, net of underwriting discounts and offering costs |  | 30356 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Proceeds from exercise of stock options/warrants | 3062 | 177 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Proceeds from settlement of loan to stockholder |  | 17700 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Borrowings on credit facility | 22000 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Repayments of borrowings on credit facility | (22000) | (25000) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Proceeds from the term loan |  | 30000 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Repayments of the term loan |  | (30000) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Cash received (paid) on notes payable | (28) | 21 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Cash paid to acquire treasury stock |  | (50003) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Cash paid to acquire portion of non-controlling interest |  | (54) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net cash used in financing activities | 3034 | (26803) |
| Effects of exchange rate changes on cash and cash equivalents | (178) | 35 |
| Net decrease in cash and cash equivalents | (9061) | (43491) |
| Cash and cash equivalents at beginning of the period | 28690 | 72181 |
| Cash and cash equivalents at end of the period | $19629 | $28690 |

---

------

 **RECONCILIATION FROM GAAP NET INCOME TO NON-GAAP ADJUSTED EBITDA**

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three Months Ended December 31,** | **Three Months Ended December 31,** | **Year Ended December 31,** | **Year Ended December 31,** |
| | **2022** | **2021** | **2022** | **2021** |
| | **(in thousands)** | **(in thousands)** | **(in thousands)** | **(in thousands)** |
| Net income | $(2810) | $(3417) | $7814 | $18992 |
| Depreciation and amortization | 460 | 512 | 1901 | 2069 |
| Interest income | (21) | (23) | (51) | (127) |
| Interest expense | 45 | 41 | 258 | 360 |
| Income tax expense | 16 | (1040) | 3027 | 5237 |
| **EBITDA** | (2310) | (3927) | 12949 | 26531 |
| Stock-based compensation (a) | 1727 | 1739 | 7384 | 3380 |
| Unrealized (gain)/loss on derivative instruments (b) | (190) | (843) | (6606) | (2093) |
| Foreign currency (gain)/loss (b) | (1895) | 75 | (1387) | 2088 |
| Loss on extinguishment of debt (c) |  | 132 |  | 132 |
| Impairment of intangible assets (d) | 6714 |  | 6714 |  |
| Other adjustments (e) |  | 3424 | 1240 | 6824 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Adjusted EBITDA** | $4046 | $600 | $20294 | $36862 |

---

(a)Non-cash charges related to stock-based compensation, which vary from period to period depending on volume and vesting timing of awards and forfeitures. We adjusted for these charges to facilitate comparison from period to period.

(b)Unrealized gains or losses on derivative instruments and foreign currency gains or losses are not considered in our evaluation of our ongoing performance.

(c)Non-cash loss on extinguishment of debt related to the early pay down of the 2021 Term Loan with the IPO proceeds which we do not consider in our evaluation of ongoing performance.

(d)Non-cash intangible asset impairment charge of $7 million related to the Runa trademarks and distributor relationships.

(e)Reflects other charges inclusive of legal costs, an impairment loss related to assets held for sale, and other non-recurring expenses (including costs related to public company readiness preparation in 2021 and a 2021 two-year management incentive program structured differently from other regular employee compensation).

------

**SUPPLEMENTAL INFORMATION**

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **NET SALES** | **NET SALES** | **NET SALES** | **NET SALES** |
| | **Three Months Ended**<br>**December 31,** | **Three Months Ended**<br>**December 31,** | **Year Ended**<br>**December 31,** | **Year Ended**<br>**December 31,** |
| **(in thousands)** | **2022** | **2021** | **2022** | **2021** |
| **Americas segment** |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Vita Coco Coconut Water | $58030 | $55628 | $275964 | $231858 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Private Label | 19760 | 14182 | 88173 | 80639 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other | 1932 | 3148 | 9485 | 11394 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Subtotal | $79722 | $72958 | $373622 | $323891 |
| **International segment** |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Vita Coco Coconut Water | $8460 | $8193 | $38570 | $34639 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Private Label | 3334 | 4359 | 12855 | 14007 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other | 475 | 1074 | 2740 | 6976 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Subtotal | $12268 | $13626 | $54165 | $55622 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total net sales | $91990 | $86584 | $427787 | $379513 |

---

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **COST OF GOODS SOLD & GROSS PROFIT** | **COST OF GOODS SOLD & GROSS PROFIT** | **COST OF GOODS SOLD & GROSS PROFIT** | **COST OF GOODS SOLD & GROSS PROFIT** |
|  | **Three Months Ended**<br>**December 31,** | **Three Months Ended**<br>**December 31,** | **Year Ended**<br>**December 31,** | **Year Ended**<br>**December 31,** |
| **(in thousands)** | **2022** | **2021** | **2022** | **2021** |
| **Cost of goods sold** |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Americas segment | $57515 | $52597 | $278130 | $222027 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;International segment | 12042 | 12400 | 46296 | 44338 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total cost of goods sold | $69557 | $64997 | $324426 | $266365 |
| **Gross profit** |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Americas segment | $22207 | $20361 | $95492 | $101864 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;International segment | 226 | 1226 | 7869 | 11284 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total gross profit | $22433 | $21587 | $103361 | $113148 |
| **Gross margin** |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Americas segment | 27.9% | 27.9% | 25.6% | 31.5% |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;International segment | 1.8% | 9.0% | 14.5% | 20.3% |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Consolidated | 24.4% | 24.9% | 24.2% | 29.8% |

---

------

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **VOLUME (CE)** | **VOLUME (CE)** | **VOLUME (CE)** | **VOLUME (CE)** |
| | **Three Months Ended**<br>**December 31,** | **Three Months Ended**<br>**December 31,** | **Year Ended**<br>**December 31,** | **Year Ended**<br>**December 31,** |
| **(in thousands)** | **2022** | **2021** | **2022** | **2021** |
| **Americas segment** |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Vita Coco Coconut Water | 6189 | 5614 | 29458 | 25096 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Private Label | 1850 | 1649 | 9063 | 9292 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other | 156 | 363 | 1248 | 1194 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Subtotal | 8195 | 7626 | 39769 | 35582 |
| **International segment\*** |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Vita Coco Coconut Water | 1216 | 1166 | 5628 | 5056 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Private Label | 457 | 555 | 1783 | 1883 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other | 7 | 18 | 46 | 231 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Subtotal | 1680 | 1739 | 7457 | 7170 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Total volume (CE)** | 9875 | 9365 | 47226 | 42752 |

---

*Note: A CE is a standard volume measure used by management which is defined as a case of 12 bottles of 330ml liquid beverages or the same liter volume of oil.* 

\*International Other excludes minor volume that is treated as zero CE

<br>